Patrick Mauro Investment Advisor INC. decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 74.3% in the third quarter, HoldingsChannel.com reports. The fund owned 12,225 shares of the biopharmaceutical company’s stock after selling 35,387 shares during the period. Patrick Mauro Investment Advisor INC.’s holdings in Bristol Myers Squibb were worth $763,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Financial Freedom LLC purchased a new position in Bristol Myers Squibb during the 3rd quarter valued at $26,000. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $27,000. Addison Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $32,000. William Mack & Associates Inc. bought a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at about $35,000. Finally, Groupe la Francaise boosted its stake in shares of Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Down 0.1%
Bristol Myers Squibb stock opened at $63.39 on Monday. Bristol Myers Squibb Company has a one year low of $45.26 and a one year high of $68.64. The stock has a fifty day moving average of $61.90 and a 200 day moving average of $60.31. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The stock has a market cap of $129.57 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 0.33 and a beta of 0.20.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $1.63 earnings per share. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on BMY shares. Cantor Fitzgerald decreased their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, October 8th. Guggenheim reaffirmed a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, Piper Sandler reduced their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $65.46.
Read Our Latest Stock Analysis on Bristol Myers Squibb
Insider Buying and Selling
In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Julia Haller sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
